Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
56 hedge funds and large institutions have $18M invested in Asterias Biotherapeutics Inc. Series A in 2015 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 10 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
9% more capital invested
Capital invested by funds: $16.5M → $18M (+$1.55M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 58 → 56 (-2)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $69K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$1.22M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$340K |
| 3 |
SIM
Spark Investment Management
New York
|
+$316K |
| 4 |
State Street
Boston,
Massachusetts
|
+$303K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$88.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$200K |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$194K |
| 3 |
Goldman Sachs
New York
|
-$108K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$91K |
| 5 |
Jane Street
New York
|
-$62K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PP
51
Paloma Partners
Greenwich,
Connecticut
| – | -$54K | -13,966 | Closed |
|
52
RhumbLine Advisers
Boston,
Massachusetts
| – | -$43K | -11,199 | Closed |
|
53
SG Americas Securities
New York
| – | -$42K | -10,735 | Closed |
|
54
M&T Bank
Buffalo,
New York
| – | -$39K | -10,028 | Closed |
|
55
AssetMark Inc
Concord,
California
| – | +$60 | +13 | New |
|
|
VCM
56
Versant Capital Management
Phoenix,
Arizona
| – | +$240 | +52 | New |
|
AST Hedge Fund Activity: Q4 2015 in Review
56 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q4 2015, worth a combined $18M — up 9.4% from $16.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of AST and 9 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 14 added.
The largest buyer was Thrivent Financial for Lutherans, opening a new position worth an estimated $1.22M. The largest seller was Vanguard Group, cutting an estimated $200K.
- 56 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q4 2015, down from 58 in Q3 2015.
- Funds reported $18M of Asterias Biotherapeutics Inc. Series A stock for Q4 2015, up 9.4% quarter-over-quarter.
- 9 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q4 2015 and 10 closed out, a net change of -1 holder.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q4 2015 was Thrivent Financial for Lutherans, an estimated $1.22M added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q4 2015 was Vanguard Group, an estimated $200K sold.
Based on aggregated 13F filings for Q4 2015.